Industry News
The latest pharmaceutical and supplement industry news — regulation updates, safety alerts, market trends, and research breakthroughs.
Amylyx Pharmaceuticals Achieves Breakthrough in Post-Bariatric Care
Amylyx reports positive Phase 3 results for avexitide in treating post-bariatric hypoglycemia, marking the first successful trial addressing this dangerous complication.
FDA Grants Accelerated Approval to Bristol Myers Squibb's Zenbexus
Bristol Myers Squibb's Zenbexus receives FDA accelerated approval for multiple myeloma, expanding treatment options for patients with this challenging blood cancer.
FDA Approves Centanafadine as First Triple Reuptake Inhibitor for ADHD
The FDA has approved centanafadine (Simtriyo), marking the first triple reuptake inhibitor for ADHD treatment with a novel mechanism targeting three neurotransmitters.
FDA Issues Urgent Warning on Toxic Yellow Oleander in Supplements
FDA testing reveals dangerous yellow oleander contamination in dietary supplements, triggering urgent safety warnings about cardiac and neurological risks to consumers.
Food To Live Recalls 9 Green Powders After 45 Salmonella Cases
FDA announces expanded recall of Food To Live green powder supplements following multi-state salmonella outbreak affecting 45 people across 23 states.
AMA Calls for Stricter Federal Regulation of Botanical Supplements
American Medical Association adopts new policy advocating enhanced FDA oversight of dietary supplements, citing safety concerns as millions use botanicals daily.
AI-Designed Drugs Reach Phase 3 Trials in Industry Milestone
First AI-designed therapeutics enter late-stage human testing, validating artificial intelligence's role in pharmaceutical development and signaling potential transformation.
Eli Lilly Takes Legal Action Against Counterfeit Weight-Loss Drug Sellers
Pharmaceutical giant files lawsuits against six companies as unauthorized versions of its breakthrough triple-hormone obesity treatment flood the market amid supply constraints.
Novo Nordisk, AWS Launch AI Co-Innovation Hub in London
Danish pharma giant partners with Amazon Web Services to establish dedicated AI facility for drug discovery, signaling industry shift toward operational AI transformation.
AI-Discovered Drugs Cut Adverse Events by 32% in Landmark Study
Multi-agent AI framework study reveals drugs targeting cell-specific genes show dramatically lower side effect rates and higher market success, marking breakthrough in drug safety.
FDA Proposes Mandatory GRAS Notification in Major Regulatory Shift
FDA's proposed rule would make GRAS notifications mandatory, creating significant compliance challenges for food, supplement, and OTC manufacturers across the industry.
Big Pharma Deepens China Biotech Investments Despite Tensions
Major pharmaceutical companies are expanding partnerships with Chinese biotech firms, signaling confidence in innovation potential and market opportunities despite geopolitical headwinds.
Sector Rotation Drives 83% Pharma Stock Surge as Investors Flee Tech
Portfolio managers pivot from mega-cap tech to pharmaceutical innovation plays, signaling major capital reallocation that could reshape pharma valuations and M&A activity.
Mayo Clinic's AI-Designed Drug Shows Promise Against Pancreatic Cancer
Mayo Clinic researchers unveil an AI-powered experimental drug showing encouraging preclinical results for pancreatic cancer, marking a significant milestone in computational drug discovery.
Tarsus Pharmaceuticals Acquires Alkeus for $450M in Strategic Expansion
Tarsus Pharmaceuticals announces $450M acquisition of Alkeus Pharmaceuticals, marking continued consolidation in specialty pharma as mid-cap companies expand pipelines.
P&G Acquires Thorne for $3.8B in Major Wellness Market Expansion
Procter & Gamble's $3.8 billion acquisition of Thorne marks a strategic shift as consumer goods giants target the premium supplement sector amid regulatory scrutiny.
FDA Proposes Heavy Fines for Clinical Trial Reporting Failures
The FDA contacts over 2,200 sponsors about missing trial results as part of sweeping enforcement action targeting non-compliance with federal reporting requirements.
VR Technology Transforms Drug Discovery with Atomic-Scale Visualization
New collaborative VR platform enables researchers to visualize and manipulate drug molecules at atomic scale, marking a significant advancement in pharmaceutical discovery methods.
Heavy Metal Contamination in Spices, Supplements Sparks Regulatory Review
New academic review highlights lead and heavy metal risks in dietary supplements and spices, signaling potential FDA regulatory tightening amid contamination concerns.
Big Pharma Braces for $26.5B Patent Cliff in 2026
Major pharmaceutical companies face $26.5 billion in revenue losses as blockbuster drug patents expire in 2026, triggering industry restructuring and M&A activity.